cytarabine and Cardiotoxicity

cytarabine has been researched along with Cardiotoxicity in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (33.33)	24.3611
2020's	2 (66.67)	2.80

Authors

Authors	Studies
Fortin, MC; Grammatopoulos, TN; LaCroix, AS; Manca, D; Tan, L; Wang, Q	1
Akhter, N; Altman, JK; Canaani, J; Cascino, GJ; Foran, JM; Furiasse, N; Ky, B; Litzow, MR; Luger, S; Rademaker, A; Rigolin, V; Tallman, MS; Voss, WB	1
Allen, K; Castellino, SM; Cooper, TM; Keller, FG; Metts, JL; Minson, KA; Monroe, C; Sabnis, HS; Woods, WG	1

Trials

1 trial(s) available for cytarabine and Cardiotoxicity

Article	Year
Two-dimensional speckle-tracking strain detects subclinical cardiotoxicity in older patients treated for acute myeloid leukemia. Echocardiography (Mount Kisco, N.Y.), 2019, Volume: 36, Issue:11 Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cardiotoxicity; Clofarabine; Cytarabine; Daunorubicin; Echocardiography; Female; Follow-Up Studies; Heart Ventricles; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Retrospective Studies; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left	2019

Article

Year

Two-dimensional speckle-tracking strain detects subclinical cardiotoxicity in older patients treated for acute myeloid leukemia.

Echocardiography (Mount Kisco, N.Y.), 2019, Volume: 36, Issue:11

Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cardiotoxicity; Clofarabine; Cytarabine; Daunorubicin; Echocardiography; Female; Follow-Up Studies; Heart Ventricles; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Retrospective Studies; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left

2019

Other Studies

2 other study(ies) available for cytarabine and Cardiotoxicity

Article	Year
Lower cardiotoxicity of CPX-351 relative to daunorubicin plus cytarabine free-drug combination in hiPSC-derived cardiomyocytes in vitro. Scientific reports, 2023, Nov-29, Volume: 13, Issue:1 Topics: Anthracyclines; Antibiotics, Antineoplastic; Cardiotoxicity; Cytarabine; Daunorubicin; Drug Combinations; Humans; Induced Pluripotent Stem Cells; Liposomes; Myocytes, Cardiac; Topoisomerase II Inhibitors	2023
A strategy to reduce cumulative anthracycline exposure in low-risk pediatric acute myeloid leukemia while maintaining favorable outcomes. Leukemia research, 2020, Volume: 96 Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Child; Child, Preschool; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Female; Follow-Up Studies; Humans; Infant; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Survival Rate; Young Adult	2020

Article

Year

Lower cardiotoxicity of CPX-351 relative to daunorubicin plus cytarabine free-drug combination in hiPSC-derived cardiomyocytes in vitro.

Scientific reports, 2023, Nov-29, Volume: 13, Issue:1

Topics: Anthracyclines; Antibiotics, Antineoplastic; Cardiotoxicity; Cytarabine; Daunorubicin; Drug Combinations; Humans; Induced Pluripotent Stem Cells; Liposomes; Myocytes, Cardiac; Topoisomerase II Inhibitors

2023

A strategy to reduce cumulative anthracycline exposure in low-risk pediatric acute myeloid leukemia while maintaining favorable outcomes.

Leukemia research, 2020, Volume: 96

Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Child; Child, Preschool; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Female; Follow-Up Studies; Humans; Infant; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Survival Rate; Young Adult

2020